DoH–Abu Dhabi & Opus Genetics partner to advance ground-breaking gene therapy research for inherited retinal diseases

At the BIO 2024 International Convention, The Department of Health – Abu Dhabi (DoH) signed a Memorandum of Understanding with Opus Genetics, a clinical-stage gene therapy company. Their collaboration aims to hasten the development of gene therapies for inherited retinal diseases (IRD) in the UAE.

IRD affects around 5% of the Arabian Gulf population, causing significant vision loss. Leveraging UAE's Emirati Genome Programme and Opus Genetics' expertise, they plan to expedite preclinical testing and clinical trials for IRD treatments, benefiting patients in Abu Dhabi and beyond.

Abu Dhabi's diverse population, genomic excellence, and efficient research approval process make it an ideal location for gene therapy trials. This partnership underscores the commitment to innovative research and therapy development, aiming to improve the lives of IRD patients globally.

The collaboration between UAE's Emirati Genome Programme and Opus Genetics promises to accelerate the development of groundbreaking gene therapies, potentially providing vital treatments for IRD patients worldwide.